Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia

Sponsor

Lund University Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT01025778

Collaborator

(none)

Enrollment

Location

Arm

Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Despite substantial progress in the treatment pediatric acute leukemia a significant number of children will experience primary or secondary resistance to the treatment. In other words it will be not possible to achieve remission using standard chemotherapy (primary resistance) or the patients will develop chemotherapy resistant relapse (secondary resistance). Children failing to achieve remission or children relapsing after previous allogeneic stem cell transplantation have short life expectancy and palliative treatment still remains the most reasonable option as the escalation of conventional chemotherapy is not longer effective.

The role of Graft versus Leukemia effect was postulated as one of the mechanisms contributing to the leukemia control/eradication after transplantation of hematopoietic stem cells.

In this study the investigators combine intensified multiagent Clofarabine containing chemotherapy with post-induction treatment intensification using reduced intensity conditioning followed by haploidentical hematopoietic stem cell transplantation. Introducing a new drug to the treatment of resistant leukemia the investigators want to achieve a response which allows us to proceed to immediate haploidentical transplantation. Using a haploidentical donor the investigators can avoid time consuming search for an unrelated donor and perform the transplantation at the optimal time-point. Combating therapy resistant leukemia the investigators would like to evoke and utilize potential Graft-versus-Leukemia effect which is much more pronounced in the haploidentical setting, as it is well documented that allogeneic transplantation with a matched donor is not effective in resistant disease. The use of best KIR mismatch donor and post-transplant donor lymphocyte infusion will be implemented in order to develop/intensify graft versus leukemia effect.

Condition or Disease	Intervention/Treatment	Phase
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia	Drug: Clofarabine for remission induction Drug: Etoposide for remission induction Drug: Cyclophosphamide for remission induction Drug: Clofarabine in conditioning before transplantation Drug: Thiotepa in conditioning before transplantation Drug: Melfalan in conditioning before transplantation Procedure: Haploidentical transplantation of T-cell depleted graft Procedure: Donor lymphocyte infusion	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

7 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Clofarabine Based Remission Induction Followed by Haploidentical Stem Cell Transplantation in Children With Refractory Hematological Malignancies

Study Start Date :

Dec 1, 2009

Actual Primary Completion Date :

Dec 1, 2012

Actual Study Completion Date :

Dec 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Remission induction and haplo-SCT Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.	Drug: Clofarabine for remission induction Drug: Etoposide for remission induction Drug: Cyclophosphamide for remission induction Drug: Clofarabine in conditioning before transplantation Drug: Thiotepa in conditioning before transplantation Drug: Melfalan in conditioning before transplantation Procedure: Haploidentical transplantation of T-cell depleted graft Procedure: Donor lymphocyte infusion

Arm

Intervention/Treatment

Experimental: Remission induction and haplo-SCT

Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.

Drug: Clofarabine for remission induction

Drug: Etoposide for remission induction

Drug: Cyclophosphamide for remission induction

Drug: Clofarabine in conditioning before transplantation

Drug: Thiotepa in conditioning before transplantation

Drug: Melfalan in conditioning before transplantation

Procedure: Haploidentical transplantation of T-cell depleted graft

Procedure: Donor lymphocyte infusion

Outcome Measures

Primary Outcome Measures

Event free survival [1 year from transplantation]

Secondary Outcome Measures

Evaluation of induction efficacy by response rate and the number of children proceeding to transplant [3 months from induction start]
Tolerance, safety and quality of life [1 year from transplantation]
Hematological and immunological recovery [100 days fron tranplantation]
Incidence of graft versus host disease [100 days from transplantation]

Eligibility Criteria

Criteria

Ages Eligible for Study:

1 Year to 21 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Target population

Refractory acute lymphoblastic leukemia

Chemoresistant isolated or combined bone marrow relapse
Relapse after during/after conventional treatment
Relapse ≥6 months after allogeneic stem cell transplantation
Primary induction failure
Isolated extramedullary relapse after previous HSCT (>6 months)

Refractory acute myeloblastic leukemia including sAML

Chemoresistant relapse
Relapse after during/after conventional treatment
Relapse ≥6 months after allogeneic stem cell transplantation
Primary induction failure

Inclusion criteria to start induction treatment with multidrug regimen

Age ≥ 1 and ≤21 years
Patients with previous HCST ≥ 6 m
Provide signed written informed consent patients', and patients' parents /guardians

Older children should be capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent as well.

Cardiac output SF ≥25%
Have adequate renal and hepatic functions as indicated by the following laboratory values:

Calculated creatinine clearance ≥90 ml/min/1.73 m2
Serum bilirubin ≤1.5 X upper limit of normal (ULN)
Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 X ULN
Alkaline phosphatase ≤ 2.5 X ULN

Performance score of ≥70% (Lansky or Karnofsky)
A suitable haploidentical family member available for stem cell donation, > 18 years of age, fulfilling institutional criteria for blood and marrow donation.
Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.

Inclusion criteria to proceed to transplant after induction

Cardiac output SF ≥25%
Have adequate renal and hepatic functions as indicated by the following laboratory values:

Calculated creatinine clearance ≥90 ml/min/1.73 m2
Serum bilirubin ≤1.5 X upper limit of normal (ULN)
Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 X ULN
Alkaline phosphatase ≤ 2.5 X ULN

Performance score of ≥70% (Lansky or Karnofsky)
A suitable haploidentical family member available for stem cell donation, > 18 years of age, fulfilling institutional criteria for blood and marrow donation.
Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.
Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.

Exclusion Criteria:

Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea.

The patient must have recovered from all acute toxicities from any previous therapy.

Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.
Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
Pregnant or lactating patients.
Any significant concurrent malignant disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.